Active Ingredient History
Beractant, also known by the trade name of Survanta, is a modified bovine pulmonary surfactant containing bovine lung extract, to which synthetic DPPC, tripalmitin and palmitic acid are added. The composition provides 25 mg/mL phospholipids, 0.5 to 1.75 mg/mL triglycerides, 1.4 to 3.5 mg/mL free fatty acids, and <1.0 mg/mL total surfactant proteins. As an intratracheal suspension, it can be used for the prevention and treatment of neonatal respiratory distress syndrome. Survanta is manufactured by Abbvie. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Breast Neoplasms (Phase 2)
Bronchopulmonary Dysplasia (Phase 2/Phase 3)
Burkitt Lymphoma (Phase 2)
Carcinoma, Squamous Cell (Phase 2)
Carcinoma, Verrucous (Phase 2)
Cardiovascular Diseases (Phase 1)
Coronary Artery Disease (Phase 4)
Ductus Arteriosus, Patent (Phase 4)
Head and Neck Neoplasms (Phase 1)
Hodgkin Disease (Phase 2)
Infant, Low Birth Weight (Phase 2/Phase 3)
Infant, Newborn (Phase 2/Phase 3)
Infant, Premature (Phase 2/Phase 3)
Infant, Premature, Diseases (Phase 4)
Infant, Small for Gestational Age (Phase 2/Phase 3)
Leukemia, Eosinophilic, Acute (Phase 2)
Leukemia, Hairy Cell (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia-Lymphoma, Adult T-Cell (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Leukemia, Myeloid, Chronic-Phase (Phase 2)
Leukemia, Myelomonocytic, Chronic (Phase 2)
Leukemia, Neutrophilic, Chronic (Phase 2)
Lymphoma (Phase 2)
Lymphoma, B-Cell, Marginal Zone (Phase 2)
Lymphoma, Follicular (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 2)
Lymphoma, Mantle-Cell (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Multiple Myeloma (Phase 2)
Myelodysplastic Syndromes (Phase 2)
Myeloproliferative Disorders (Phase 2)
Nausea (Phase 1/Phase 2)
Neoplasm Metastasis (Phase 2)
Neoplasms (Phase 1/Phase 2)
Neuroblastoma (Phase 2)
Ovarian Neoplasms (Phase 2)
Primary Myelofibrosis (Phase 2)
Respiratory Distress Syndrome (Phase 4)
Respiratory Insufficiency (Phase 4)
Sezary Syndrome (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Testicular Neoplasms (Phase 2)
Tongue Neoplasms (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue